Search
Search results
50 results found
News
HIV Vaccine Summary
TEST TEXT
Contact
Kathryn E. Stephenson, MD, MPH Center of Virology and Vaccine Research Beth Israel Deaconess Medical Center 330 Brookline Ave, E/CLS-1037 Boston, MA T: 617-735-4556 F: 617-735-4470 kstephen@bidmc.harvard.edu [she/her/hers] k__stephensonmd
Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV
Mayer, Bryan T., Lily Zhang, Allan C. deCamp-, -Michel Nussenzweig, Kathryn E. Stephenson, Boris Julg-, and -Huub C. Gelderblom. 2024. “Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People Without HIV”. Pharmaceutics 16.
Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19.
Stephenson, Kathryn, Mathieu Le Gars, Jerald Sadoff-, -Hanneke Schuitemaker, and Dan H. Barouch. 2021. “Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19.”. JAMA 325(15):1535-1544.
Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial
Stephenson, Kathryn E., Boris Julg, Sabrina Tan-, -Bette Korber, and Dan H. Barouch. 2021. “Safety, Pharmacokinetics and Antiviral Activity of PGT121, a Broadly Neutralizing Monoclonal Antibody Against HIV-1: A Randomized, Placebo-Controlled, Phase 1 Clinical Trial”. Nature Medicine 27: 1718-24.
Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
Alter, Galit, Jingyou Yu, Jinyan Liu-, -Kathryn E. Stephenson-, -Hanneke Schuitemaker, and Dan H. Barouch. 2021. “Immunogenicity of Ad26.COV2.S Vaccine Against SARS-CoV-2 Variants in Humans”. Nature 596 (7871): 268-72.
HIV Antibody Fc N-Linked Glycosylation Is Associated with Viral Rebound
Offersen, Rasmus, Wen-Han Yu, Eileen P. Scully-, -Kathryn E. Stephenson-, -Ole S. Sogaard, and Galit Alter. 2020. “HIV Antibody Fc N-Linked Glycosylation Is Associated With Viral Rebound”. Cell Reports 33 (11): 108502.
Triple bNAb cocktail provides long-term virologic control in people with HIV
Key takeaways: Eighty-three percent of patients maintained virologic suppression after the bNAb cocktail for 28 weeks. Forty-two percent had virologic suppression for 38 to 44 weeks despite the decline of bNAb concentrations.